ArticleFrontiers in medicine2026
The impact of the COVID-19 pandemic on liver health: exploring shifts in social and psychosocial determinants of steatosis and fibrosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: The COVID-19 pandemic profoundly disrupted social structures, psychological well-being, and lifestyle behaviors, yet the collective impact on steatotic liver disease (SLD) and fibrosis remains unclear. This study aimed to examine whether the relationships of social, psychosocial, and behavioral factors with metabolic dysfunction-associated SLD (MASLD), metabolic alcohol-related liver disease (MetALD), ALD, and liver fibrosis varied across pandemic periods. Methods: We conducted a repeated cross-sectional analysis of 6,090 adults from the National Health and Nutrition Examination Survey (NHANES) 2017-March 2020 (pre-pandemic) and 2021-2023 (pandemic), using vibration-controlled transient elastography and comprehensive social, psychosocial, and lifestyle measures. Weighted prevalence and Firth's logistic regression assessed associations and pandemic interactions via ratios of odds ratios (RORs). Results: Age-standardized MASLD prevalence declined from 32.2% to 28.6%, especially among men, whereas advanced fibrosis nearly doubled from 2.6% to 4.2%, mainly in women. Pandemic-period interactions revealed substantial shifts in risk profiles. Higher income lost its pre-pandemic protective association with MetALD (ROR = 0.21), while unemployment increased MetALD risk in women. Depressive symptoms strengthened ALD risk in men during the pandemic (OR = 5.31; ROR = 6.73), but became less relevant for MetALD, particularly among women. Physical activity, which was previously protective for MASLD and ALD, lost significance post-pandemic. Current smoking markedly amplified ALD risk (OR rising from 3.49 to 17.08), whereas former smoking provided protection against MASLD in men. Dietary inflammation (DII) became inversely associated with fibrosis during the pandemic, and longer weekend sleep offered protective benefits for women. Conclusion: The pandemic period was associated with substantial changes in the epidemiology and psychosocial-behavioral correlates of SLD and fibrosis, with notable sex-specific differences.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.